(Massacesi L. è parte de "EBMT Autoimmune Disease Working Party"). Abstract: In 1997, the first consensus guidelines for haematopoietic SCT (HSCT) in autoimmune diseases (ADs) were published, while an international coordinated clinical programme was launched. These guidelines provided broad principles for the field over the following decade and were accompanied by comprehensive data collection in the European Group for Blood and Marrow Transplantation (EBMT) AD Registry. Subsequently, retrospective analyses and prospective phase I/II studies generated evidence to support the feasibility, safety and efficacy of HSCT in several types of severe, treatment-resistant ADs, which became the basis for larger-scale phase II and III studies. In parallel, there has also been an era of immense progress in biological therapy in ADs. The aim of this document is to provide revised and updated guidelines for both the current application and future development of HSCT in ADs in relation to the benefits, risks and health economic considerations of other modern treatments. Patient safety considerations are central to guidance on patient selection and HSCT procedural aspects within appropriately experienced and Joint Accreditation Committee of International Society for Cellular Therapy and EBMT accredited centres. A need for prospective interventional and non-interventional studies, where feasible, along with systematic data reporting, in accordance with EBMT policies and procedures, is emphasized.Bone Marrow Transplantation advance online publication, 17 October 2011.

Haematopoietic SCT in severe autoimmune diseases: updated guidelines of the European Group for Blood and Marrow Transplantation / Snowden JA; Saccardi R; Allez M; Ardizzone S; Arnold R; Cervera R; Denton C; Hawkey C; Labopin M; Mancardi G; Martin R; Moore JJ; Passweg J; Peters C; Rabusin M; Rovira M; van Laar JM; Farge D; on behalf of the EBMT Autoimmune Disease Working Party (ADWP) and Paediatric Diseases Working Party (PDWP); Massacesi L.. - In: BONE MARROW TRANSPLANTATION. - ISSN 0268-3369. - ELETTRONICO. - 47(6):(2011), pp. 1-21. [10.1038/bmt.2011.185]

Haematopoietic SCT in severe autoimmune diseases: updated guidelines of the European Group for Blood and Marrow Transplantation.

MASSACESI, LUCA
2011

Abstract

(Massacesi L. è parte de "EBMT Autoimmune Disease Working Party"). Abstract: In 1997, the first consensus guidelines for haematopoietic SCT (HSCT) in autoimmune diseases (ADs) were published, while an international coordinated clinical programme was launched. These guidelines provided broad principles for the field over the following decade and were accompanied by comprehensive data collection in the European Group for Blood and Marrow Transplantation (EBMT) AD Registry. Subsequently, retrospective analyses and prospective phase I/II studies generated evidence to support the feasibility, safety and efficacy of HSCT in several types of severe, treatment-resistant ADs, which became the basis for larger-scale phase II and III studies. In parallel, there has also been an era of immense progress in biological therapy in ADs. The aim of this document is to provide revised and updated guidelines for both the current application and future development of HSCT in ADs in relation to the benefits, risks and health economic considerations of other modern treatments. Patient safety considerations are central to guidance on patient selection and HSCT procedural aspects within appropriately experienced and Joint Accreditation Committee of International Society for Cellular Therapy and EBMT accredited centres. A need for prospective interventional and non-interventional studies, where feasible, along with systematic data reporting, in accordance with EBMT policies and procedures, is emphasized.Bone Marrow Transplantation advance online publication, 17 October 2011.
2011
47(6)
1
21
Snowden JA; Saccardi R; Allez M; Ardizzone S; Arnold R; Cervera R; Denton C; Hawkey C; Labopin M; Mancardi G; Martin R; Moore JJ; Passweg J; Peters C; Rabusin M; Rovira M; van Laar JM; Farge D; on behalf of the EBMT Autoimmune Disease Working Party (ADWP) and Paediatric Diseases Working Party (PDWP); Massacesi L.
File in questo prodotto:
File Dimensione Formato  
2012 Haematopoietic SCT in severe autoimmune....pdf

Accesso chiuso

Tipologia: Versione finale referata (Postprint, Accepted manuscript)
Licenza: Tutti i diritti riservati
Dimensione 783.06 kB
Formato Adobe PDF
783.06 kB Adobe PDF   Richiedi una copia

I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificatore per citare o creare un link a questa risorsa: https://hdl.handle.net/2158/631287
Citazioni
  • ???jsp.display-item.citation.pmc??? 74
  • Scopus 237
  • ???jsp.display-item.citation.isi??? 218
social impact